JP2014501707A5 - - Google Patents

Download PDF

Info

Publication number
JP2014501707A5
JP2014501707A5 JP2013537210A JP2013537210A JP2014501707A5 JP 2014501707 A5 JP2014501707 A5 JP 2014501707A5 JP 2013537210 A JP2013537210 A JP 2013537210A JP 2013537210 A JP2013537210 A JP 2013537210A JP 2014501707 A5 JP2014501707 A5 JP 2014501707A5
Authority
JP
Japan
Prior art keywords
composition
composition according
cationic surfactant
glucagon
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013537210A
Other languages
English (en)
Japanese (ja)
Other versions
JP5894174B2 (ja
JP2014501707A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2011/052139 external-priority patent/WO2012059762A1/en
Publication of JP2014501707A publication Critical patent/JP2014501707A/ja
Publication of JP2014501707A5 publication Critical patent/JP2014501707A5/ja
Application granted granted Critical
Publication of JP5894174B2 publication Critical patent/JP5894174B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013537210A 2010-11-03 2011-11-03 グルカゴンを含む新規組成物 Expired - Fee Related JP5894174B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40972310P 2010-11-03 2010-11-03
US40978510P 2010-11-03 2010-11-03
US61/409,785 2010-11-03
US61/409,723 2010-11-03
US201161503104P 2011-06-30 2011-06-30
US201161503178P 2011-06-30 2011-06-30
US61/503,104 2011-06-30
US61/503,178 2011-06-30
PCT/GB2011/052139 WO2012059762A1 (en) 2010-11-03 2011-11-03 Novel composition comprising glucagon

Publications (3)

Publication Number Publication Date
JP2014501707A JP2014501707A (ja) 2014-01-23
JP2014501707A5 true JP2014501707A5 (enExample) 2014-12-04
JP5894174B2 JP5894174B2 (ja) 2016-03-23

Family

ID=44913349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537210A Expired - Fee Related JP5894174B2 (ja) 2010-11-03 2011-11-03 グルカゴンを含む新規組成物

Country Status (6)

Country Link
US (1) US9023985B2 (enExample)
EP (1) EP2635296B1 (enExample)
JP (1) JP5894174B2 (enExample)
CA (1) CA2816114C (enExample)
ES (1) ES2533601T3 (enExample)
WO (2) WO2012059764A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
US9254332B2 (en) 2013-03-15 2016-02-09 Arecor Limited Stable aqueous formulations of adenovirus vectors
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016077220A1 (en) * 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN107949374B (zh) * 2015-09-04 2022-04-08 莱迪杜德制药公司 稳定的胰高血糖素溶液
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
KR20190026748A (ko) 2016-06-07 2019-03-13 아도시아 인간 글루카곤 및 말단-그래프트된 코폴리아미노산을 포함하는 주사가능한 수용액 형태의 조성물
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
CA3084700A1 (en) 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
WO2019110837A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
US20190275110A1 (en) 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectale aqueous solution comprising human glucagon and a co-polyamino acid
EP3731858A1 (fr) * 2017-12-07 2020-11-04 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3083087A1 (fr) 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3067247A1 (fr) 2018-06-07 2018-12-14 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
IL298396A (en) * 2020-05-22 2023-01-01 Hanmi Pharm Ind Co Ltd Liquid formulation of long-acting conjugate of glucagon derivative

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1202607A (en) * 1968-01-10 1970-08-19 Novo Terapeutisk Labor As Improvements in or relating to stable glucagon solutions and their preparation
JPH0651637B2 (ja) 1985-03-28 1994-07-06 エーザイ株式会社 ペプタイドの吸着防止組成物
JP2001507722A (ja) * 1997-11-06 2001-06-12 オーボン コーポレイション 薬物送達のための安定化乾燥薬学的組成物、およびそれを調製する方法
WO1999047160A1 (en) 1998-03-13 1999-09-23 Novo Nordisk A/S Stabilized aqueous peptide solutions
DK1093370T3 (da) * 1998-06-30 2006-05-22 Takeda Pharmaceutical Farmaceutisk præparat til behandling af diabetes
JP2007204498A (ja) * 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP4147234B2 (ja) * 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、カートリッジ及び吐出装置
US7115791B2 (en) 2002-12-19 2006-10-03 Exxonmobil Chemical Patents Inc. Method and apparatus for controlling effluent composition in oxygenates to olefins conversion
JP2008505087A (ja) 2004-06-29 2008-02-21 ディオベックス， インコーポレイテッド インスリン誘発性低血糖の予防および制御のための組成物ならびに方法
WO2007056362A2 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CA2674354A1 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
EA017849B1 (ru) 2007-02-15 2013-03-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соагонисты глюкагоновых/glp-1-рецепторов
US20100184675A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent
AU2008318986B2 (en) 2007-10-30 2014-12-04 Indiana University Research And Technology Corporation Glucagon antagonists
WO2009058734A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
EA020326B9 (ru) 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
PA8830501A1 (es) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
DK2490708T3 (da) 2009-10-22 2013-04-15 Biodel Inc Stabiliserede glucagon-opløsninger

Similar Documents

Publication Publication Date Title
JP2014501707A5 (enExample)
JP2018138578A5 (enExample)
CO2019012773A2 (es) Sistemas autoenderezables y componentes y métodos relacionados
JP5894174B2 (ja) グルカゴンを含む新規組成物
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
HRP20251088T1 (hr) Upotreba dugodjelujućih peptida glp‑1
MX2011009174A (es) Formulaciones de insulina para captacion rapida.
AR092470A1 (es) Formulaciones acuosas estables de adalimumab
MX2020009411A (es) Capsula resistente al abuso.
HRP20190777T1 (hr) Brzodjelujući pripravci inzulina
MX2010003776A (es) Composiciones de insulina inyectables de accion rapida.
HK1207577A1 (en) Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
AR092862A1 (es) Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
RU2014115996A (ru) Автоматическое инъекционное устройство
JP2017503017A5 (enExample)
JP2015512392A5 (enExample)
WO2014047657A3 (en) Drug pump devices and needle-insertion mechanisms
JP2012051891A5 (enExample)
JP2014526369A5 (enExample)
FI3479819T3 (fi) Stabiili nestemäinen farmaseuttinen valmiste
HRP20221367T1 (hr) Brzodjelujući inzulinski pripravci
RU2016119746A (ru) Стабильный состав инсулина глулизин
ECSP17040923A (es) Derivados de glucagón con estabilidad mejorada
MX2017012506A (es) Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan.
BR112015030850B1 (pt) Dispositivo de injeção